| 1. |
-
A guide to Strategic Partnerships : Structure collaboration between academia and wider society
- 2020
-
Editorial collection (pop. science, debate, etc.)abstract
- To facilitate work on strategic partnerships, 16 higher education institutions in Sweden have produced a guide, within a partnership with funding from Vinnova. The “Strategic Partnership Guide” is a description of and a guide to strategic partnerships. It is formulated from the perspective of a higher education institution. The target group is staff working with collaboration in the area of operational support at Swedish universities and colleges, to provide support in their professional role. The guide may also be useful for vice-chancellors, management teams at higher education institutions, executive boards or academic leaders, to help familiarise themselves with this kind of collaboration. The guide provides an introduction to strategic partnerships and compiles experiences and lessons learned that can facilitate work when getting started with or further developing partnerships.
|
|
| 2. |
-
Handledning för strategiska partnerskap : Strukturerad samverkan mellan akademin och det omgivande samhället
- 2020
-
Editorial collection (pop. science, debate, etc.)abstract
- För att underlätta arbetet med strategiska partnerskap har 16 lärosäten i Sverige tagit fram en handledning, inom ett samarbete med finansiering från Vinnova. “Handledning för strategiska partnerskap” är en beskrivning av och vägledning till strategiska partnerskap. Den är formulerad ur ett lärosätes perspektiv. Målgruppen är personal som arbetar med samverkan inom verksamhetsstöd vid svenska universitet och högskolor, som ett stöd i deras yrkesutövning. Men även rektorer, lärosätesledningar, styrelser och akademiska ledare kan ha användning av handledningen, för att sätta sig in i villkoren för denna typ av samverkan. Handledningen ger en introduktion till strategiska partnerskap och samlar erfarenheter och lärdomar som kan underlätta arbetet att komma igång med eller vidareutveckla partnerskap.
|
|
| 3. |
- Dahlén, Torsten, et al.
(author)
-
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors : Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
- 2022
-
In: American Journal of Hematology. - : Wiley. - 0361-8609 .- 1096-8652. ; 97:4, s. 421-430
-
Journal article (peer-reviewed)abstract
- Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the treatment is associated with adverse events. In a large cohort-study, we assessed the morbidity in 1328 Swedish CML chronic phase patients diagnosed 2002-2017 and treated with TKIs, as compared to that in carefully matched control individuals. Several Swedish patient registers with near-complete nationwide coverage were utilized for data acquisition. Median follow-up was 6 (IQR, 3-10) years with a total follow-up of 8510 person-years for the full cohort. Among 670 analyzed disease categories, the patient cohort showed a significantly increased risk in 142 while, strikingly, no category was more common in controls. Increased incidence rate ratios/IRR (95% CI) for more severe events among patients included acute myocardial infarction (AMI) 2.0 (1.5-2.6), heart failure 2.6 (2.2-3.2), pneumonia 2.8 (2.3-3.5), and unspecified sepsis 3.5 (2.6-4.7). When comparing patients on 2nd generation TKIs vs. imatinib in a within-cohort analysis, nilotinib generated elevated IRRs for AMI (2.9; 1.5-5.6) and chronic ischemic heart disease (2.2; 1.2-3.9), dasatinib for pleural effusion (11.6; 7.6-17.7) and infectious complications, for example, acute upper respiratory infections (3.0; 1.4-6.0). Our extensive real-world data reveal significant risk increases of severe morbidity in TKI-treated CML patients, as compared to matched controls, particularly for 2nd generation TKIs. Whether this increased morbidity may also translate into increased mortality, thus preventing CML patients to achieve a normalized overall survival, needs to be further explored.
|
|
| 4. |
- Eriksson, Hjalmar, et al.
(author)
-
Evaluation of the Swedish participation in the Halden Reactor Project 2006–2014
- 2016
-
Reports (other academic/artistic)abstract
- This is a report on the evaluation of the Swedish participation in the Halden Reactor Project 2006-2014. The study has consisted in evaluating the types and extent of added value from the Swedish participation in the Halden Reactor Project, and to determine what additional added value the participation could supply for the Swedish authority.It can be concluded from the study that the impacts from the Halden Reactor Project are extensive and wide ranging, reaching beyond the scope of what has been possible to cover in the evaluation. This limitation is mainly due to the long history and continuity of the collaboration, extending far beyond the scope of the study. The evaluation further concludes that the Halden Reactor Project has come to play a systemic role for the nuclear sector in Sweden, supplying significant portions of the data underlying safety oriented research and development within the areas concerned. These impacts have mainly been realized in industry, and are promoted in particular by voluntary, bottom-up coordination and engagement by industry stakeholders. Academia has seen little added value from the Swedish participation in the Halden Reactor Project, while the public sector has benefited somewhat, however, its engagement has been limited in comparison with peer countries Finland and Switzerland.The evaluation team recommends that the Swedish stakeholders continue funding the participation in the Halden Reactor Project. Additionally, the Swedish authority’s funding of research infrastructures in general should be safeguarded by acknowledging this type of investment in the research strategy. The distinct and fundamental role of research infrastructures in innovation systems is being increasingly recognized, and the participation in the Halden Reactor Project is a clear example of the value of such institutions for the continuous expansion of knowledge. Furthermore, the Swedish strategy for benefiting from the Halden Reactor Project should be further elaborated, taking into account the possible actions of strengthening coordination, increasing funding to supplementary domestic research, and reviewing the responsibilities of the officials administering the Swedish participation.
|
|
| 5. |
- Flygt, Hjalmar, et al.
(author)
-
Long-term tolerability and efficacy after initial PegIFN-alpha addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
- 2021
-
In: European Journal of Haematology. - : Wiley-Blackwell. - 0902-4441 .- 1600-0609. ; 107:6, s. 617-623
-
Journal article (peer-reviewed)abstract
- Objectives Treatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-alpha in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-alpha (PegIFN-alpha) in combination with dasatinib (DAS) in CML-CP. Methods Forty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 mu g/wk of PegIFN-alpha was added and increased to 25 mu g/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data. Results After 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study. Conclusion Initial addition of PegIFN-alpha to DAS shows good long-term efficacy without increased toxicity.
|
|
| 6. |
- Flygt, Hjalmar, et al.
(author)
-
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
- 2021
-
In: European Journal of Haematology. - : John Wiley & Sons. - 0902-4441 .- 1600-0609. ; 107:6, s. 617-623
-
Journal article (peer-reviewed)abstract
- ObjectivesTreatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-α in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-α (PegIFN-α) in combination with dasatinib (DAS) in CML-CP.MethodsForty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 μg/wk of PegIFN-α was added and increased to 25 μg/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data.ResultsAfter 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study.ConclusionInitial addition of PegIFN-α to DAS shows good long-term efficacy without increased toxicity.
|
|
| 7. |
- Flygt, Hjalmar, et al.
(author)
-
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
- 2021
-
In: British Journal of Haematology. - : John Wiley & Sons. - 0007-1048 .- 1365-2141. ; 193:5, s. 915-921
-
Journal article (peer-reviewed)abstract
- Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (>= 1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4 center dot 8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41 center dot 1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.
|
|
| 8. |
- Lindholm, Lars Hjalmar, et al.
(author)
-
The impact of health care advice given in primary care on cardiovascular risk
- 1995
-
In: BMJ (Clinical research ed.). - 0959-8138. ; 310:6987, s. 1105-1109
-
Journal article (peer-reviewed)abstract
- Limited additional benefit was gained from being in the group receiving the intensive health care advice. It is difficult to make an important impact on cardiovascular risk in primary care by using only the practice staff. Better methods of communicating the messages need to be devised.
|
|
| 9. |
- Nilsson, Mats, et al.
(author)
-
Contemporary carbon accumulation in a boreal oligotrophic minerogenic mire - a significant sink after accounting for all C-fluxes
- 2008
-
In: Global Change Biology. - : Wiley. - 1354-1013 .- 1365-2486. ; 14:10, s. 2317-2332
-
Journal article (peer-reviewed)abstract
- Based on theories of mire development and responses to a changing climate, the current role of mires as a net carbon sink has been questioned. A rigorous evaluation of the current net C-exchange in mires requires measurements of all relevant fluxes. Estimates of annual total carbon budgets in mires are still very limited. Here, we present a full carbon budget over 2 years for a boreal minerogenic oligotrophic mire in northern Sweden (64 degrees 11'N, 19 degrees 33'E). Data on the following fluxes were collected: land-atmosphere CO2 exchange (continuous Eddy covariance measurements) and CH4 exchange (static chambers during the snow free period); TOC (total organic carbon) in precipitation; loss of TOC, dissolved inorganic carbon (DIC) and CH4 through stream water runoff (continuous discharge measurements and regular C-concentration measurements). The mire constituted a net sink of 27 +/- 3.4 (+/- SD) g C m(-2) yr(-1) during 2004 and 20 +/- 3.4 g C m(-2) yr(-1) during 2005. This could be partitioned into an annual surface-atmosphere CO2 net uptake of 55 +/- 1.9 g C m(-2) yr(-1) during 2004 and 48 +/- 1.6 g C m(-2) yr(-1) during 2005. The annual NEE was further separated into a net uptake season, with an uptake of 92 g C m(-2) yr(-1) during 2004 and 86 g C m(-2) yr(-1) during 2005, and a net loss season with a loss of 37 g C m(-2) yr(-1) during 2004 and 38 g C m(-2) yr(-1) during 2005. Of the annual net CO2-C uptake, 37% and 31% was lost through runoff (with runoff TOC > DIC >> CH4) and 16% and 29% through methane emission during 2004 and 2005, respectively. This mire is still a significant C-sink, with carbon accumulation rates comparable to the long-term Holocene C-accumulation, and higher than the C-accumulation during the late Holocene in the region.
|
|
| 10. |
- Stavreus-Evers, A., et al.
(author)
-
Co-existence of heparin-binding epidermal growth factorlike growth factor and pinopodes in human endometrium at the time of implantation
- 2002
-
In: Molecular human reproduction. - : Oxford University Press (OUP). - 1360-9947 .- 1460-2407. ; 8:8, s. 765-769
-
Journal article (peer-reviewed)abstract
- Pinopodes have been suggested to be markers of uterine receptivity. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is expressed in increasing amounts in the secretory phase endometrium and is considered to be important for the human implantation process. The aim of this study was to investigate a possible co-existence of pinopodes and HB-EGF in the normal human endometrium. Endometrial biopsies were obtained from women with normal menstrual cycles. The biopsies were examined by scanning electron microscopy for the detection of pinopodes, by immunohistochemistry for the expression of HB-EGF protein, and by confocal microscopy to determine if HB-EGF was present on the surface of the pinopodes. The expression of HB-EGF in luminal and glandular epithelium was highest when fully developed pinopodes were present. Using confocal microscopy it was shown that HB-EGF was present both inside the luminal epithelial cells and on the surface of pinopodes. These findings suggest that HB-EGF might play a role in both the attachment and penetration steps in the human implantation process. Furthermore, the immunohistochemical staining demonstrates that HB-EGF can be used as a marker for the implantation window.
|
|
